A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
14/09/2021at 07:43

Snipr Biome to collaborate with US cancer hospital

The Danish company will examine the effect of new CRISPR therapies as a treatment for immune therapy side effects alongside the MD Anderson Cancer Center.
Snipr Biome CEO Christian Grøndahl | Photo: EY / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

Biotech company Snipr Biome has found a partner to help develop new treatments using CRISPR technology, which targets the human microbiome.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Novo Nordisk / PR

    Novo Nordisk enters into collaboration with Danish crispr firm Snipr

    For subscribers

  • Photo: Brian Snyder/Reuters/Ritzau Scanpix

    Vertex spends billions on CRISPR technology in search of diabetes cure

    For subscribers

  • Snipr Biome CEO Christian Grøndahl | Photo: EY / PR

    Carb-X investment gives Snipr Biome validation before going to clinic

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Foto: Stine Bidstrup
Pharma & biotech

Potential blockbuster submitted by Novo Nordisk for European approval

The EMA can begin reviewing hemophilia treatment concizumab, which used to carry the orphan drug badge until recently, when the company decided not to take advantage of the status.
  • Novo Nordisk renounces orphan drug title for potential blockbuster
  • Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Photo: Viatris/PR.
Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

For subscribers

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

For subscribers

Photo: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Photo: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Photo: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Further reading

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk predicts wide range for 2023 sales growth

The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)

For subscribers

Anders Hinsby (left), Thomas Kirkegaard Jensen, and Anders Vadsholt | Foto: Anne Bæk/Ritzau Scanpix
Pharma & biotech

Orphazyme trio founds new firm focused on neurology and rare diseases

Anders Hinsby, Anders Vadsholt, and Thomas Kirkegaard Jensen – all three key figures from now-defunct biotech company Orphazyme – have established a new company using experiences from the past.

For subscribers

Photo: Robert Galbraith/Reuters/Ritzau Scanpix
Pharma & biotech

Amgen takes on Abbvie blockbuster Humira with unusual price plan

Abbvie’s multibillion-dollar generating anti-inflammatory drug, Humira, is about to face competition for the first time, as Amgen launches an almost identical product using an unconventional strategy.

For subscribers

Latest news

  • Potential blockbuster submitted by Novo Nordisk for European approval – 13:51
  • Novo Nordisk sues Viatris over copycat Wegovy – 12:46
  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, sets new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
  • Pfizer hopes Covid-19 sales will increase in the long run – 31 Jan
See all

Jobs

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Commercial Director

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Application Manager

  • Experienced Patent Counsel

See all jobs

Jobs

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Commercial Director

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Application Manager

  • Experienced Patent Counsel

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge